Abstract
Oral lichen planus (OLP) is a chronic inflammatory mucosal disease that cell-mediated immunological mechanisms are involved in pathogenesis. The objective of this study was to investigate the expression of CD44 isoforms including CD44s, CD44v5, and CD44v6 in biopsy specimens and saliva from OLP patients. Thirty-one OLP patients and 30 healthy subjects were enrolled in this study. Immunohistochemical methods were used to detect the expression of CD44 isoforms in oral epithelia, and enzyme-linked immunosorbent assay (ELISA) was performed to measure levels of salivary CD44 isoforms. Our results demonstrated that expression of CD44v6 in oral epithelia from OLP patients was significantly decreased in comparison to controls (p = 0.021). Levels of salivary CD44s and CD44v5 from OLP patients were significantly higher than those from controls (p = 0.007 and p = 0.002, respectively). In summary, our findings provided additional evidence that the pathological stress, such as chronic inflammation, altered the expression of CD44 isoforms in oral epithelia and saliva of OLP patients.
Similar content being viewed by others
References
Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting, Part 1, viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:40–51.
Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998;9:86–22.
Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand. 2001;59:174–7.
Sugerman PB, Savage NW, Walsh IJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13:351–67.
Simark-Mattsson C, Bergenholtz G, Jontell M, Eklund C, Seymour GJ, Sugerman PB, et al. Distribution of interleukin-2,-4,-10, tumour necrosis factor-. a. and transforming growth factor-. b. mRNAs in oral lichen planus. Arch Oral Biol. 1999;44:499–07.
Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med. 2003;32:77–3.
Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-. k. B-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005;114:278–83.
Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF-. a. in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med. 2006;35:161–6.
Bascones C, Gonzalez-Moles MA, Esparza G, Bravo M, Acevedo A, Gil-Montoya JA, et al. Apoptosis and cell cycle arrest in oral lichen planus: hypothesis on their possible influence on its malignant transformation. Arch Oral Biol. 2005;50:873–81.
Kim SG, Chae CH, Cho BO, Kim HN, Kim HJ, Kim IS, et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J Oral Pathol Med. 2006;35:37–45.
Farthing PM, Matear P, Crunchley AT. The activation of Langerhans cells in oral lichen planus. J Oral Pathol Med. 1990;19:81–5.
Santoro A, Majorana A, Roversi L, Gentili F, Marrelli S, Vermi W. Recruitment of dendritic cells in oral lichen planus. J Pathol. 2005;205:426–34.
Konter U, Kellner I, Hoffmeister B, Sterry W. Induction and up-regulation of adhesion receptors in oral and dermal lichen planus. J Oral Pathol Med. 1990;19:459–63.
Ramirez-Amador V, Dekker NP, Lozada-Nur F, Mirowski GW, MacPhail LA, Regezi JA. Altered interface adhesion molecules in oral lichen planus. Oral Dis. 1996;2:188–92.
Regezi JA, Dekker NP, MacPhail LA, Lozada-Nur F, McCalmont TH. Vascular adhesion molecules in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:682–90.
Chaiyarit P, Ma N, Hiraku Y, Pinlaor S, Yongvanit P, Jintakanon D, et al. Nitrative and oxidative DNA damage in oral lichen planus in relation to human oral carcinogenesis. Cancer Sci. 2005;96:553–9.
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA. 1992;89:12160–4.
Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell. 1989;56:1057–62.
Goldstein LA, Butcher EC. Indentification of mRNA that encodes an alternative form of H-CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics. 1990;32:389–97.
Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 1991;10:343–8.
Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, et al. Activated human lymphocytes and aggressive non-Hodgkin’s lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 1993;177:897–04.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1301–13.
Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol. 1992;116:817–25.
Ehnis T, Dieterich W, Bauer M, Lampe B, Schuppan D. A chondroitin/dermatan sulfate form of CD44 is a receptor for collagenXIV (undulin). Exp Cell Res. 1996;229:388–97.
Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 1996;271:509–12.
Jones M, Tussey L, Athanasou N, Jackson DG. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem. 2000;275:7964–74.
Murakami S, Miyake K, June CH, Kincade PW, Hodes RJ. IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. J Immunol. 1990;145:3618–27.
Ariel A, Novick D, Rubinstein M, Dinarello CA, Lider O, Hershkoviz R. IL-12 and IL-18 induce MAP kinase dependent adhesion of T cells to extracellular matrix components. J Leukoc Biol. 2002;72:192–8.
Reid SD, Pockley AG. Cytokine regulation of CD44 expression on rat intestinal epithelial cells. Immunol Invest. 2000;29:271–86.
Gee K, Lim W, Ma W, Nandan D, Diaz-Mitoma F, Kozlowski M. Differential role of CD44 expression by LPS and TNF-. a. in human monocytic cells: distinct involvement of C-jun-N-terminal kinase in LPS-induced CD44 expression. J Immunol. 2002;169:5660–72.
Cichy J, Pure E. The liberation of CD44. J Cell Biol. 2003;161:839–43.
Kawano T, Yanoma S, Nakamura Y, Shiono O, Kokatu T, Kubota A, et al. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol. 2005;26:308–13.
Katoh S, Matsubara Y, Taniguchi H, Fukushima K, Mukae H, Kadota J, et al. Characterization of CD44 expressed on alveolar macrophages in patients with diffuse panbronchiolitis. Clin Exp Immunol. 2001;126:545–50.
Fuchs S, Rolauffs B, Arndt S, Tibesku CO, Prehm P. CD44H and the isoforms CD44v5 and CD44v6 in the synovial fluid of the osteoarthritic human knee joint. Osteoarthritis Cartilage. 2003;11:839–44.
Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005;3:735–9.
Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, et al. Membrane type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893–04.
Sherman L, Wainwright D, Ponta H, Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev. 1998;12:1058–71.
Ghaffari S, Smadja-Joffe F, Ooostendorp R, Levelsque JP, Dougherty G, Eaves A, et al. CD44 isoforms in normal and leukemic hematopoiesis. Exp Hematol. 1999;27:978–93.
Gunthert U, Schwarzler C, Wittig B, Laman J, Ruiz P, Stauder R, et al. Functional involvement of CD44, a family of cell adhesion molecules, in immune response, tumour progression and haematopoiesis. Adv Exp Med Biol. 1998;451:43–9.
Stoop R, Gal I, Glant TT, McNeish JD, Mikecz K. Trafficking of CD44-deficient murine lymphocytes under normal and inflammatory conditions. Eur J Immunol. 2002;32:2532–42.
McKallip RJ, Do Y, Fisher MT, Robertson JL, Nagarkatti PS, Nagarkatti M. Role of CD44 in activation-induced cell death: CD44-deficient mice exhibit enhanced T cell response to conventional and superantigens. Int Immunol. 2002;14:1015–26.
Pure E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med. 2001;7:213–21.
Yamada M, Nakano K, Yasumoto K, Tanaka Y. CD44: Functional relevance to inflammation and malignancy. Histol Histopathol. 2002;17:945–50.
MacKay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71–82.
Levesque MC, Haynes BF. In vitro culture of human peripheral blood monocytes induces hyaluronan binding and up-regulates monocyte variant CD44 isoform expression. J Immunol. 1996;156:1557–65.
Teder Vandivier PRW, Jiang D, Liang J, Cohn L, Pure E, Henson PM, et al. Resolution of lung inflammation by CD44. Science. 2002;296:155–8.
Haberhauer G, Kittl EM. Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid arthritis. J Rheumatol. 1998;25:1442–4.
Schlosser W, Gansauge F, Schlosser S, Gansauge S, Beger HG. Low serum levels of CD44, CD44v6, and neopterin indicate immune dysfunction in chronic pancreatitis. Pancreas. 2001;23:335–40.
Pfister K, Wittig BM, Mueller-Molaian I, Remberger K, Zeitz M, Stallmach A. Decreased CD44v6 expression in lamina propria lymphocytes of patients with inflammatory bowel disease. Exp Mol Pathol. 2001;71:186–93.
Neppelberg E, Loro LL, Oijordsbakken G, Johannessen AC. Altered CD40 and E-cadherin expression- putative role in oral lichen planus. J Oral Pathol Med. 2007;36:153–60.
Thongprasom K, Luengvisut P, Wongwatanakit A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med. 2003;32:315–22.
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055–61.
Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell. 2007;18:76–83.
Sutinen M, Kainulainen T, Hurskainen T, Vesteriund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer. 1998;77:2239–45.
Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001;28:72–82.
Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum. 1999;42:659–68.
Cairns AP, Crockard AD, McConnell JR, Courtney PA, Bell AL. Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis. 2001;60:950–5.
Reinisch W, Heider KH, Oberhuber G, Dejaco C, Mullner M, Adolf GR, et al. Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn’s disease. GUT. 1998;43:375–82.
Rosenberg WMC, Prince C, Kaklamanis L, Fox SB, Jackson DG, Simmons DL, et al. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn’s disease. Lancet. 1995;345:1205–9.
Kemppainen T, Tammi R, Tammi M, Agren U, Julkunen R, Bohm J, et al. Elevated expression of hyaluronan and its CD44 receptor in the duodenal mucosa of celiac patients. Histopathology. 2005;46:64–72.
Levesque MC, Mackin DA, Fleming JA, St Clair EW. Serum levels of soluble CD44 in Primary Sjögren’s syndrome. J Rheumatol. 2000;27:1444–9.
Acknowledgements
This research work was supported by The Thailand Research Fund (# MRG4880152). The authors would like to express our thanks to Dr. Wichian Chowsrikul for providing biopsy specimens used as positive controls and to Dr. Richard L. Gregory for his contribution on reviewing this manuscript. The authors also thank the Research Unit in Oral Diseases, Faculty of Dentistry, Chulalongkorn University for previous support. Finally, we would like to thank the staff of the Department of Oral Diagnosis, Faculty of Dentistry, Khon Kaen University and the staff of the Departments of Oral Medicine and Oral Pathology, Faculty of Dentistry, Chulalongkorn University for their assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s10875-007-9136-5
Rights and permissions
About this article
Cite this article
Chaiyarit, P., Thongprasom, K., Satayut, S. et al. Alteration of the Expression of CD4 Isoforms in Oral Epithelia and Saliva from Patients with Oral Lichen Planus. J Clin Immunol 28, 26–34 (2008). https://doi.org/10.1007/s10875-007-9128-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-007-9128-5